U.S. Diabetic Neuropathy Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-31　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 682.3 Mn
2033 年預估規模: USD 962.8 Mn
年複合成長率 CAGR: 7.2%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-31頁數 168報告編號 CMI5356

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

U.S. Diabetic Neuropathy Market, By Drug (Tricyclic Antidepressants (Amitriptyline, Nortyptyline, Imipramine, Desipramine), SSRI (Paroxetine, Citalopram), Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine), Opioids (Tramadol, Tapentadol, Oksikodon), SNRIs (Duloxetine), Other Drugs (Capsaicin, Lidocaine, Botilinum Toxin)), By Type (Peripheral Neuropathy, Proximal Neuropathy, Autonomic Neuropathy, Focal Neuropathy), By Route of Administration (Oral, Topical, Injection (Intramuscular)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

報告摘要

Diabetic neuropathy is a serious and common complication of type 1 and type 2 diabetes. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower leg, it develops slowly, sometimes over the course of decades. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. Peripheral neuropathy is the most common form of neuropathy. Over time, high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage your nerves. High blood glucose levels can also damage the small blood vessels that nourishes the nerves with oxygen and nutrients. There is no cure for diabetic neuropathy but the nerve pain can be managed with medication and exercise. Market Dynamics Increasing adoption of inorganic strategies such as collaborative agreement by key market players is expected to drive the U.S. diabetic neuropathy market over the forecast period. For instance, in June 2020, NeuroMetrix, Inc., a medical device company, announced that they had signed a collaborative agreement with BioMedix, a manufacturer of diagnostic and surgical equipment, to comarket DPNCheck for peripheral neuropathy detection within medicare advantage. This agreement will provide complementary diagnostic tests to physicians and health plans by combining results from multiple diagnostic tests into one data exchange file for the electronic medical record system. Key features of the study • This report provides an in-depth analysis of the U.S. diabetic neuropathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the U.S. diabetic neuropathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The U.S. diabetic neuropathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. diabetic neuropathy market Market Segmentation • By Drug o Tricyclic Antidepressants  Amitriptyline  Nortyptyline  Imipramine  Desipramine o SSRI  Paroxetine  Citalopram o Anticonvulsants  Gabapentin  Pregabalin  Carbamazepine o Opioids  Tramadol  Tapentadol  Oksikodon o SNRIs  Duloxetine o Other Drugs  Capsaicin  Lidocaine  Botilinum Toxin • By Type o Peripheral Neuropathy o Proximal Neuropathy o Autonomic Neuropathy o Focal Neuropathy • By Route of Administration o Oral o Topical o Injection (Intramuscular) • By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Key Players Insights o Eli Lilly and Company o Johnson & Johnson Services, Inc. o Novartis AG o Pfizer, Inc. o GSK plc. o Glenmark Pharmaceuticals Ltd. o Lupin o Regenacy Pharmaceuticals, Inc. o Alembic Pharmaceuticals Limited o Abbott o Ionis Pharmaceuticals o NeuroMetrix, Inc. o Tissue Tech, Inc. o Averitas Pharma, Inc.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Drug  Market Snapshot, By Type  Market Snapshot, By Route of Administration  Market Snapshot, By Distribution Channel o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities  Market Trends o Impact Analysis o Partnership and Collaboration Scenario o Recent Product Launches and Approvals o Market Trends o Regulatory Scenario o PEST Analysis o Reimbursement Scenario o Cost of therapy o Brand Mapping 4. U.S. Diabetic Neuropathy Market, By Drug, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Tricyclic Antidepressants  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Amitriptyline  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Nortyptyline  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Imipramine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Desipramine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o SSRI  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Paroxetine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Citalopram  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Anticonvulsants  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Gabapentin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Pregabalin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Carbamazepine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Others (Oxcarbazepine, Topiramate and Others)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Opioids  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Tramadol  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Tapentadol  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Oksikodon  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o SNRIs  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Duloxetine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Other Drugs  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million o Capsaicin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Lidocaine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Botilinum Toxin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 5. U.S. Diabetic Neuropathy Market, By Type, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Peripheral Neuropathy  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Proximal Neuropathy  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Autonomic Neuropathy  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Focal Neuropathy  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 6. U.S. Diabetic Neuropathy Market, By Route of Administration, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Oral  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Topical  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Injection (Intramuscular)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 7. U.S. Diabetic Neuropathy Market, By Distribution Channel, 2026 – 2033, (USD Million) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Hospital Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Retail Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Online Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) 8. Competitive Landscape o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Johnson & Johnson Services, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Pfizer, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o GSK plc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Glenmark Pharmaceuticals Ltd.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Lupin  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Regenacy Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Alembic Pharmaceuticals Limited  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Abbott  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Ionis Pharmaceuticals  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o NeuroMetrix, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Tissue Tech, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Averitas Pharma, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 9. Section o Research Methodology o About Us

提及公司

Eli Lilly and CompanyJohnson & Johnson Services, Inc.Novartis AGPfizer, Inc.GSK plc.Glenmark Pharmaceuticals Ltd.LupinRegenacy Pharmaceuticals, Inc.Alembic Pharmaceuticals LimitedAbbottIonis PharmaceuticalsNeuroMetrix, Inc.Tissue Tech, Inc.Averitas Pharma, Inc.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們